Société ArcticZymes Technologies ASA
Actions
AZT
NO0010014632
Recherche biotechnologique et médicale
Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
25,95 NOK | +0,78 % | -0,76 % | -38,21 % |
25/06 | ArcticZymes Technologies nomme un nouveau président | MT |
13/05 | ArcticZymes Technologies ASA annonce la démission de membres de son conseil d'administration | CI |
Métier
Ventes par activité
NOK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Enzymes
100,0
%
| 137 | 100,0 % | 119 | 100,0 % | -13,16 % |
Ventes par région
NOK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
44,7
%
| 60 | 44,1 % | 53 | 44,7 % | -11,94 % |
Lithuania
29,0
%
| 28 | 20,5 % | 35 | 29,0 % | +23,15 % |
Other Countries in Europe
11,0
%
| 18 | 13,0 % | 13 | 11,0 % | -26,47 % |
Germany
6,0
%
| 12 | 8,8 % | 7 | 6,0 % | -40,48 % |
Rest of World
3,8
%
| 16 | 11,5 % | 5 | 3,8 % | -71,34 % |
France
2,9
%
| - | - | 3 | 2,9 % | - |
Italy
2,4
%
| 3 | 1,9 % | 3 | 2,4 % | +9,83 % |
Norway
0,2
%
| 0 | 0,3 % | 0 | 0,2 % | -48,86 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Michael Akoh
CEO | Chief Executive Officer | - | 18/09/23 |
Børge Sørvoll
DFI | Director of Finance/CFO | 49 | 01/10/14 |
Darren Ellis
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/22 |
Chief Operating Officer | 56 | - | |
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/00 |
Dirk Hahneiser
SAM | Sales & Marketing | 56 | 01/01/22 |
Dino DiCamillo
SAM | Sales & Marketing | 66 | 01/01/12 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/00 |
Chief Operating Officer | 56 | - | |
Bernd Striberny
BRD | Director/Board Member | - | - |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 50 871 390 | 35 904 791 ( 70,58 %) | 0 | 70,58 % |
Coordonnées société
ArcticZymes Technologies ASA
Siva Innovasjonssenter Sykehusveien 23
9019, Tromsø
+47 77 64 89 00
http://www.arcticzymes.comSociétés du groupe
Nom | Catégorie et Secteur |
---|---|
ArcticZymes AS
ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. |
Medical Specialties
|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. |
Pharmaceuticals: Major
|
Secteur
Ventes par activité
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
-38,21 % | 123 M | |
+23,13 % | 52,73 Md | |
+37,49 % | 39 Md | |
-8,73 % | 38,52 Md | |
+28,09 % | 30,38 Md | |
-12,26 % | 26,39 Md | |
+10,57 % | 26,08 Md | |
+45,05 % | 14,15 Md | |
+32,23 % | 12,6 Md | |
-6,56 % | 11,51 Md |
- Bourse
- Actions
- Action AZT
- Société ArcticZymes Technologies ASA